Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

Sara Alosaimy; Sarah C.J. Jorgensen; Abdalhamid M. Lagnf; Sarah Melvin; Ryan P. Mynatt; Travis J. Carlson; Kevin W. Garey; David Allen; Veena Venugopalan; Michael Veve; Vasilios Athans; Stephen Saw; Christine N. Yost; Susan L. Davis; Michael J. Rybak

doi:10.1093/ofid/ofaa051

Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

Sara Alosaimy
, Sarah C.J. Jorgensen
, Abdalhamid M. Lagnf
, Sarah Melvin
, Ryan P. Mynatt
, Travis J. Carlson
, Kevin W. Garey
, David Allen
, Veena Venugopalan
, Michael Veve
, Vasilios Athans
, Stephen Saw
, Christine N. Yost
, Susan L. Davis
, Michael J. Rybak

Producción científica: Article › revisión exhaustiva

49 Citas (Scopus)

Resumen

Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

Idioma original	English (US)
Número de artículo	ofaa051
Publicación	Open Forum Infectious Diseases
Volumen	7
N.º	3
DOI	https://doi.org/10.1093/ofid/ofaa051
Estado	Published - mar 1 2020
Publicado de forma externa	Sí

ASJC Scopus subject areas

Oncology
Infectious Diseases

Acceder al documento

10.1093/ofid/ofaa051

Otros archivos y enlaces

Citar esto

Alosaimy, S., Jorgensen, S. C. J., Lagnf, A. M., Melvin, S., Mynatt, R. P., Carlson, T. J., Garey, K. W., Allen, D., Venugopalan, V., Veve, M., Athans, V., Saw, S., Yost, C. N., Davis, S. L., & Rybak, M. J. (2020). Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections. Open Forum Infectious Diseases, 7(3), Artículo ofaa051. https://doi.org/10.1093/ofid/ofaa051

Alosaimy, S, Jorgensen, SCJ, Lagnf, AM, Melvin, S, Mynatt, RP, Carlson, TJ, Garey, KW, Allen, D, Venugopalan, V, Veve, M, Athans, V, Saw, S, Yost, CN, Davis, SL & Rybak, MJ 2020, 'Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections', Open Forum Infectious Diseases, vol. 7, n.º 3, ofaa051. https://doi.org/10.1093/ofid/ofaa051

@article{6f5848f9e4b34a21ad52c06608c272f9,

title = "Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections",

abstract = "Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0\% of all GNB infections. Clinical success occurred in 70.0\% of patients. Mortality and recurrence at 30 days were 7.5\% and 12.5\%, respectively. One patient experienced a probable rash due to MEV.",

keywords = "Carbapenem-resistant Enterobacteriaceae, Gram-negative infections, Meropenem-vaborbactam, Multidrug-resistant",

author = "Sara Alosaimy and Jorgensen, \{Sarah C.J.\} and Lagnf, \{Abdalhamid M.\} and Sarah Melvin and Mynatt, \{Ryan P.\} and Carlson, \{Travis J.\} and Garey, \{Kevin W.\} and David Allen and Veena Venugopalan and Michael Veve and Vasilios Athans and Stephen Saw and Yost, \{Christine N.\} and Davis, \{Susan L.\} and Rybak, \{Michael J.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2020",

month = mar,

day = "1",

doi = "10.1093/ofid/ofaa051",

language = "English (US)",

volume = "7",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "3",

}

TY - JOUR

T1 - Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

AU - Alosaimy, Sara

AU - Jorgensen, Sarah C.J.

AU - Lagnf, Abdalhamid M.

AU - Melvin, Sarah

AU - Mynatt, Ryan P.

AU - Carlson, Travis J.

AU - Garey, Kevin W.

AU - Allen, David

AU - Venugopalan, Veena

AU - Veve, Michael

AU - Athans, Vasilios

AU - Saw, Stephen

AU - Yost, Christine N.

AU - Davis, Susan L.

AU - Rybak, Michael J.

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

AB - Fourty patients were treated with meropenem-vaborbactam (MEV) for serious Gram-negative bacterial (GNB) infections. Carbapenem-resistant Enterobacteriaceae (CRE) comprised 80.0% of all GNB infections. Clinical success occurred in 70.0% of patients. Mortality and recurrence at 30 days were 7.5% and 12.5%, respectively. One patient experienced a probable rash due to MEV.

KW - Carbapenem-resistant Enterobacteriaceae

KW - Gram-negative infections

KW - Meropenem-vaborbactam

KW - Multidrug-resistant

UR - https://www.scopus.com/pages/publications/85087383431

UR - https://www.scopus.com/pages/publications/85087383431#tab=citedBy

U2 - 10.1093/ofid/ofaa051

DO - 10.1093/ofid/ofaa051

M3 - Article

AN - SCOPUS:85087383431

SN - 2328-8957

VL - 7

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 3

M1 - ofaa051

ER -

Real-world multicenter analysis of clinical outcomes and safety of meropenem-vaborbactam in patients treated for serious gram-negative bacterial infections

Resumen

ASJC Scopus subject areas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto